Philogen entered into a pharma licensing agreement with Pfizer to develop and commercialize empowered antibodies.
According to Philogen, the validated antibodies have precise specificity in diseases characterized by angiogenesis.
Pfizer has exclusive rights to develop certain (antibody-drug conjugates) ADCs and guided nanoparticles.
|Searching for more deal information? Current Partnering offers the following options:
The pharma giant is responsible for R&D and potential commercialization of candidate molecules.
The pharma licensing partnership expands on an existing relationship between the companies from January 2013 when Pfizer obtained rights to Dekavil, an investigational therapy for autoimmune diseases, from Philogen as part of a global license agreement.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies
Report: Top 50 Big Biotech Partnering and M&A Deal Trends